Emerging trends in viral infection inhibition using a chitosan-based drug delivery system.

IF 3.9 4区医学 Q1 PHARMACOLOGY & PHARMACY

Journal of Drug Targeting Pub Date : 2025-08-01 DOI:10.1080/1061186X.2025.2540858

Somayeh Kakehbaraei, Morteza Arab-Zozani, Seyran Kakebaraei

{"title":"Emerging trends in viral infection inhibition using a chitosan-based drug delivery system.","authors":"Somayeh Kakehbaraei, Morteza Arab-Zozani, Seyran Kakebaraei","doi":"10.1080/1061186X.2025.2540858","DOIUrl":null,"url":null,"abstract":"<p><p>Viral diseases damage the host's cells and weaken the host's immunity, leading to multiple relapses or lasting a long time. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a prevalent infection that can cause immunostimulation, serious medical complications or even promote the risk of side effects and fatality, especially among older adults. Due to the replication process of the viral genome, it is significant to design and develop new pharmaceuticals to alleviate the illness and global death rates attributed to infection. Chitosan, a versatile biopolymer derived from natural sources, possesses cationic properties and has been employed to produce nanoparticles (NPs). These NPs exhibit biocompatibility, biodegradability, antimicrobial and anticancer properties, non-toxicity, ready availability, and the ability to function as drug delivery systems (DDSs). The physicochemical attributes of chitosan and its NPs in the transfer of bioactive agents are detected in nanotechnology, which can enhance anti-viral efficacy. This review highlights progressions in nanoscience for chitosan-based drug delivery in treating viral diseases. New research is expected to suggest new strategies in the field of DDS for the therapeutics of infectious diseases.</p>","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-16"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Targeting","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1061186X.2025.2540858","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Viral diseases damage the host's cells and weaken the host's immunity, leading to multiple relapses or lasting a long time. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a prevalent infection that can cause immunostimulation, serious medical complications or even promote the risk of side effects and fatality, especially among older adults. Due to the replication process of the viral genome, it is significant to design and develop new pharmaceuticals to alleviate the illness and global death rates attributed to infection. Chitosan, a versatile biopolymer derived from natural sources, possesses cationic properties and has been employed to produce nanoparticles (NPs). These NPs exhibit biocompatibility, biodegradability, antimicrobial and anticancer properties, non-toxicity, ready availability, and the ability to function as drug delivery systems (DDSs). The physicochemical attributes of chitosan and its NPs in the transfer of bioactive agents are detected in nanotechnology, which can enhance anti-viral efficacy. This review highlights progressions in nanoscience for chitosan-based drug delivery in treating viral diseases. New research is expected to suggest new strategies in the field of DDS for the therapeutics of infectious diseases.

查看原文本刊更多论文

利用壳聚糖为基础的药物传递系统抑制病毒感染的新趋势。

病毒性疾病破坏宿主细胞，削弱宿主免疫力，导致多次复发或持续时间较长。严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）是一种常见的感染，可导致免疫刺激、严重的医疗并发症，甚至增加副作用和死亡的风险，尤其是在老年人中。由于病毒基因组的复制过程，设计和开发新的药物以减轻由感染引起的疾病和全球死亡率具有重要意义。壳聚糖是一种从天然来源提取的多功能生物聚合物，具有阳离子特性，已被用于生产纳米颗粒（NPs）。这些NPs具有生物相容性，生物可降解性，抗菌和抗癌特性，无毒性，现成可用性以及作为药物递送系统（dds）的能力。利用纳米技术检测壳聚糖及其NPs在生物活性物质转移过程中的理化性质，从而提高其抗病毒效果。本文综述了纳米科学在壳聚糖给药治疗病毒性疾病方面的研究进展。新的研究有望在DDS领域为传染病治疗提供新的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Targeting 医学-药学

CiteScore

9.10

自引率

0.00%

发文量

165

审稿时长

2 months

期刊介绍： Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.